Quince Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying
Portfolio Pulse from Lisa Levin
Insiders at Gaia, Inc. (GAIA), Rise Gold Corp. (RYES), and Quince Therapeutics, Inc. (QNCX) have recently made significant stock purchases. Gaia's Director Paul Sutherland acquired 1,000 shares at an average price of $2.57, following a wider-than-expected Q2 loss. Rise Gold's 10% owner V B S Investments Pty Ltd acquired 500,000 shares at an average price of $0.40, following the appointment of Mr. Daniel Oliver Jr. as a director. Quince Therapeutics' CEO Dirk Thye acquired 88,000 shares at an average price of $1.26, following a narrower Q1 loss.
August 14, 2023 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Gaia's Director Paul Sutherland acquired 1,000 shares at an average price of $2.57, following a wider-than-expected Q2 loss.
The insider purchase at Gaia could indicate confidence in the company's prospects despite the recent Q2 loss. However, the impact on the stock price is uncertain in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Quince Therapeutics' CEO Dirk Thye acquired 88,000 shares at an average price of $1.26, following a narrower Q1 loss.
The insider purchase at Quince Therapeutics could indicate confidence in the company's prospects following a narrower Q1 loss. This could have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Rise Gold's 10% owner V B S Investments Pty Ltd acquired 500,000 shares at an average price of $0.40, following the appointment of Mr. Daniel Oliver Jr. as a director.
The insider purchase at Rise Gold could indicate confidence in the company's prospects following the appointment of a new director. This could have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100